TXG - 10X Genomics - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US88025U1097

Instruments, Consumables, Software

10x Genomics Inc., a pioneering life science technology company, specializes in developing and marketing innovative instruments, consumables, and software solutions for analyzing complex biological systems. With a strong presence in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific, the company has established itself as a leader in the field of single-cell analysis.

Their product portfolio includes the Chromium, Chromium Connect, and Chromium Controller instruments, as well as microfluidic chips, slides, reagents, and other consumables. These cutting-edge tools enable researchers to gain a deeper understanding of biological systems at the single-cell level, allowing for groundbreaking discoveries in fields such as genomics, epigenetics, and immunology.

The company's single-cell solutions, which run on the Chromium instruments, offer a range of applications, including single-cell gene expression, single-cell immune profiling, and single-cell Assay for Transposase Accessible Chromatin (ATAC) solution. These solutions enable researchers to study gene activity, immune systems, and epigenetic states at an unprecedented level of resolution. Additionally, the single-cell multiome ATAC + gene expression solution allows for the simultaneous analysis of RNA and chromatin accessibility in a single cell.

10x Genomics also offers the Visium platform, which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. The Xenium platform, designed for in situ analysis, provides further insights into biological systems. The company's products and solutions cater to a diverse range of customers, including academic institutions, government agencies, biopharmaceutical companies, biotechnology firms, and other organizations.

Founded in 2012 as 10X Technologies, Inc., the company changed its name to 10x Genomics, Inc. in November 2014. Headquartered in Pleasanton, California, 10x Genomics continues to drive innovation in the life sciences, empowering researchers to uncover new insights and make meaningful discoveries.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for TXG - 10X Genomics  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for TXG - 10X Genomics  - Stock Price & Dividends

TXG Stock Overview

Market Cap in USD 2,351m
Sector Healthcare
Industry Health Information Services
GiC SubIndustry Life Sciences Tools & Services
TER 0.00%
IPO / Inception 2019-09-12

TXG Stock Ratings

Growth 5y -58.0
Fundamental -54.2
Dividend -
Rel. Performance vs Sector -9.99
Analysts 4.00/5
Fair Price Momentum 13.22 USD
Fair Price DCF -

TXG Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

TXG Growth Ratios

Growth 12m -69.90%
Growth Correlation 12m -62%
Growth Correlation 3m -91%
CAGR 5y -20.38%
CAGR/Mean DD 5y -0.43
Sharpe Ratio 12m -1.49
Alpha vs SP500 12m -109.74
Beta vs SP500 5y weekly 1.64
ValueRay RSI 47.85
Volatility GJR Garch 1y 68.12%
Price / SMA 50 -20.86%
Price / SMA 200 -52.72%
Current Volume 3366.8k
Average Volume 20d 2066.6k

External Links for TXG Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of TXG stocks?
As of July 13, 2024, the stock is trading at USD 17.49 with a total of 3,366,841 shares traded.
Over the past week, the price has changed by -6.57%, over one month by -18.08%, over three months by -49.38% and over the past year by -70.36%.
What are the forecast for TXG stock price target?
According to ValueRays Forecast Model, TXG 10X Genomics will be worth about 14.9 in July 2025. The stock is currently trading at 17.49. This means that the stock has a potential downside of -14.87%.
Issuer Forecast Upside
Wallstreet Target Price 40 129
Analysts Target Price 60.3 245
ValueRay Target Price 14.9 -14.9